# Treatment options for mucopolysaccharidosis
Treatment of mucopolysaccharidosis (MPS) aims to replace or supplement the missing enzyme, slow symptom progression, and manage complications. Because different MPS types lack different enzymes, the approach varies by type. There is no cure, but modern therapies can significantly improve quality of life and life expectancy, especially when started early.
Enzyme replacement
**How it works and its use**
In enzyme replacement, the missing or non-functioning enzyme is artificially produced and administered. These enzymes are usually given intravenously (via infusion) in a hospital or outpatient setting. The enzyme is taken up by cells and helps break down the accumulation of polysaccharides. The frequency and duration of infusions depend on the specific medication and MPS type.
For certain MPS types, enzyme replacement is also possible at home, under the guidance of a medical team. This offers more flexibility and can be less disruptive to daily life.
**Known side effects**
Infusion reactions occur regularly, with symptoms such as reactions at the injection site, fever, headache, or shortness of breath. These can usually be well managed by adjusting the infusion rate or with preparation (allergy medications). Severe reactions are rare. Over time, some patients may develop neutralizing antibodies against the enzyme, which can shorten its duration of action.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Stem Cell Transplantation
**How it works and its use**
In stem cell transplantation, healthy blood-forming stem cells from a donor (usually from cord blood or bone marrow) are introduced. These cells settle in the bone marrow and produce the missing enzyme themselves, which can prevent or slow the accumulation of polysaccharides. This can be especially effective if done early in the disease course, before serious organ damage has occurred.
Transplantation requires chemotherapy or radiation for preparation, intensive aftercare, and risk of rejection. It is a significant procedure with substantial risks, but can be transformative for certain patients, especially those with neurodegenerative forms.
**Known side effects**
Infections, anemia, bone marrow damage, graft-versus-host disease (rejection), and prolonged weakened immunity. Some patients have no suitable donor. For many patients, data are being collected on long-term outcomes.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Intracerebroventricular enzyme infusion
**How it works and its use**
For mucopolysaccharidoses that primarily affect the central nervous system (such as MPS type III), enzymes can be delivered directly to the brain via a catheter that reaches the cerebrospinal fluid. This bypasses the blood-brain barrier and ensures direct delivery of the enzyme to where it is needed.
This method often combines surgical placement of an implant system with regular infusions (usually in an outpatient setting). It is aimed at slowing cognitive and neurological decline.
**Known side effects**
Infections (meningitis), catheter obstruction or displacement, headache, inflammatory reactions in brain tissue. Surgical complications are possible but rare in specialized centers. Patients require regular neurological monitoring.
ResearchediPositive results in clinical studies, not yet standard treatment
Substrate reduction therapy
**How it works and its use**
These medications reduce the production of polysaccharides that accumulate instead of breaking them down. By inhibiting production, the body's cells become less overwhelmed. This complements enzyme replacement or serves as an alternative when enzyme replacement is not available or not well tolerated.
Substrate reduction works systemically and requires regular administration (usually orally or intravenously, depending on the medication).
**Known side effects**
This varies by medication. Many substrate reducers can cause gastrointestinal disturbances, fatigue, or affect liver values. Long-term use is continuously monitored. Some medications have more side effects than others.
ResearchediPositive results in clinical studies, not yet standard treatment
Supportive Treatment
**Cardiological care**
MPS can affect the heart and cardiovascular system (heart valves, cardiac hypertrophy, high blood pressure). Regular echocardiograms and cardiological check-ups are standard, and some patients require medication or even surgery (for example, valve replacement).
ProveniIncluded in official guidelines, or approved by EMA or FDA
**Orthopaedic intervention**
Joint problems, bone fusion and spinal instability are common. Physiotherapy, orthopaedic aids and sometimes surgery (muscle strengthening, vertebral replacement) can improve mobility and quality of life. Early attention to the cervical spine is important because instability can be serious.
ProveniIncluded in official guidelines, or approved by EMA or FDA
**Ear, nose and throat care**
Narrowing of the upper airway and hearing problems occur frequently. Speech therapy, hearing aids and sometimes surgical procedures (for example, widening of narrowed passages) may be necessary.
ProveniIncluded in official guidelines, or approved by EMA or FDA
**Dental and oral care**
Dental abnormalities and gum fusion are common. Regular dental care and specialised approaches (for example, laser therapy for gum hyperplasia) can prevent complications.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Medication support
**Pain relief and spasticity**
As neurological symptoms increase, agents for pain, spasticity or seizures are used to improve comfort and function. These are supportive, not curative.
ProveniIncluded in official guidelines, or approved by EMA or FDA
**Sleep medication and psychiatric support**
Behavioural problems, anxiety and sleep disorders can develop, especially in later stages of neurodegenerative forms. Psychological support and targeted medication help maintain quality of life.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Experimental approaches
**Gene therapy**
Research into direct correction of the missing gene (via viral vectors or other carriers) is ongoing for various MPS types. These are still in the research phase and not routinely available.
ExperimentaliOngoing in study setting, outcome still unknown
**Combination therapy**
Studies are exploring whether intraventricular enzyme infusion combined with stem cell transplantation or other approaches gives better results, especially for neurodegenerative forms.
ResearchediPositive results in clinical studies, not yet standard treatment
**Drug screening based on patient cells**
Research uses laboratory models (including patient cells) to see which existing drugs have an effect on the patient's specific mutation. This aims at future personalisation.
ResearchediPositive results in clinical studies, not yet standard treatment
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._